Welichem enters into termination agreement with Celestial and BWTP
Welichem, Celestial and BWTP have been trying to negotiate with the relevant Chinese authorities since 2012 to obtain approval of the China APA as required for the transfer
Akeso has received approval from China’s National Medical Products Administration (NMPA) for gumokimab (AK111), an anti-Interleukin-17 (IL-17) monoclonal antibody, to treat adults with moderate-to-severe plaque psoriasis.
The clinical program will follow protocols developed by a subcommittee made up of representatives of the Pediatric Heart Network (PHN), a multi-center clinical research network funded by the
The company said that patients enrolled in the trial must have a documented diagnosis of hypogonadism, or testosterone deficiency defined as having testosterone levels below 300ng/dL. About 150